EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer

NCT07698613 | Not Yet Recruiting Phase 1 DMC FDA Drug

• 2 other identifiers: BrUOG 4381929-IIR-0016
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.

Conditions

Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection; Pancreatic Cancer Borderline; Pancreatic Cancer Resectable

Keywords

ASP-1929; photoimmunotherapy; EGFR targeting antibody; laser-light activable dye IR700; IRDye 700DX; RM-1929; cetuximab sarotalocan

Outcome Measures

Primary Outcomes (2)

• Incidence of treatment related toxicities grade ≥3

  Part 1 \| Safert: The primary endpoint is grade 3 or higher ASP-1929 photoimmunotherapy treatment related toxicity within 28 days of surgery.

  From start of treatment to 28 days post surgery

• Number of Participants Reaching 6 Months Progression Free Survival

  Part 2 (expansion cohort for efficacy): The primary endpoint of this cohort is 6-month progression free survival. RECIST version 1.1 will be used to assess for response/progression

  From start of treatment to 6 months post surgery.

Study Arms (1)

ASP-1929 PIT

EXPERIMENTAL

Approximately 24 hours prior to surgery patients will receive ASP-1929, IV over 2 hours, in the outpatient clinic. ASP-1929 is an EGFR targeting antibody conjugated with a laser-light activable dye IR700. The following day patients will undergo standard surgical exploration. Patients found to be inoperable will be treated with the laser device (Alluminox platform) over 5 minutes in the operating room to activate ASP-1929 photoimmunotherapy. Activation of the IR700 dye with red light (690nm) may result in anticancer activity mediated by immunogenic cell death and necrosis, leading to activation of the immune system. \[Patients who are resectable will undergo resection of their pancreatic cancer and will not receive the laser and their tumor will subsequently be evaluated for EGFR receptor saturation.\] Part 1: There will be a 10-patient safety run-in Part 2: If Part 1 is acceptable, an additional 20 patients will receive PIT to determine preliminary efficacy in a total of 30 patients

Combination Product: ASP-1929 photoimmunotherapy

Interventions

ASP-1929 photoimmunotherapy COMBINATION_PRODUCT

Approximately 24 hours prior to surgery, patients will receive ASP-1929, IV over 2 hours, in the outpatient clinic. ASP-1929 is an EGFR targeting antibody conjugated with a laser-light activable dye IR700 (IRDye 700DX). The following day patients will undergo standard surgical exploration. Those patients found to be inoperable on surgical exploration will be treated with the laser device (Alluminox platform) over 5 minutes in the operating room to activate ASP-1929 photoimmunotherapy. Activation of the IR700 dye with red light (690nm) may result in anticancer activity mediated by immunogenic cell death and necrosis, leading to activation of the immune system.

Also known as: RM-1929, ASP-1929 PIT, cetuximab sarotalocan

ASP-1929 PIT

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Pathologically confirmed pancreatic adenocarcinoma.
• Clinically staged locally advanced or borderline resectable pancreatic adenocarcinoma.
• Completed neoadjuvant chemotherapy
• Neoadjuvant radiation is allowed
• Planned surgical exploration
• Treatment with ASP-1929 will be at least 4 - 10 weeks after last chemotherapy and radiation.
• Patients with a history of biliary obstruction must have adequate biliary drainage.
• Patients meeting the following laboratory criteria for Adequate Organ and Bone Marrow Function:
• Platelet Count ≥ 75,000/mm3. Hemoglobin ≥ 8.0 g/dL \[NOTE: Participants requiring ongoing transfusions or growth factor support to maintain hemoglobin ≥8.0 g/dL are not eligible\] Absolute neutrophil count ≥ 1,000/mm3. \[Granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1\] Alanine aminotransferase (ALT) ≤ 3×ULN Aspartate aminotransferase (AST) ≤ 3×ULN Total Bilirubin ≤ 1.5×ULN or \< 3×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) Creatinine ≤ 3×ULN
• Age ≥ 18
• ECOG performance status 0-1
• For women of pregnancy potential, a negative pregnancy test within 7 days prior to registration.
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if:

• Patients with distant metastases.
• Patients with medical co-morbidities that make them not candidates for surgical exploration
• Planned concomitant, non-protocol directed anti-cancer therapy for at least 8 weeks after ASP-1929
• Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline. Note: Subjects may be enrolled with chronic, stable Grade 2.
• History of significant (Grade ≥ 3) cetuximab infusion reactions
• Photosensitizing medications must be discontinued 4 weeks before ASP-1929 PIT treatment, unless medically required.
• No uncontrolled intercurrent illness including but not limited to symptomatic CHF, unstable angina, clinically significant severe cardiac arrhythmia, psychiatric illness or social situations that would limit compliance with study requirements.
• Any other condition which, in the investigator's opinion, deems the patient an unsuitable candidate to receive ASP-1929 and/or be exposed to PIT illumination.
• Women who are pregnant or nursing.
• Patients with concomitant malignancies not expected to cause death within 5 years are eligible.

Sponsors & Collaborators

• Rakuten Medical, Inc.: collaborator
• The Miriam Hospital: collaborator
• Brown University: lead
• Rhode Island Hospital: collaborator

Study Sites (1)

Rhode Island and the Miriam Hospitals (Brown University Health)

Providence, Rhode Island, 02903/02906, United States

Location

Central Study Contacts

Roxanne Wood, MPH

CONTACT

401-863-3000; roxanne_wood@brown.edu

BrUOG

CONTACT

BrUOG@brown.edu

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 7, 2026
• First Posted: July 13, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): March 1, 2029
• Study Completion (Estimated): September 1, 2033
• Last Updated: July 13, 2026

Record last verified: 2026-07

Locations

US (1)